+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

N

Actively Recruiting

Primary aldosteronism PA is a common cause of secondary hypertension, and its diagnosis and treatment pose significant challenges. This research investigates adrenal venous sampling AVS, which is considered the best method to distinguish between different types of PA. The study aims to address clinical, technical, and methodological questions about AVS and to understand how AVS-guided management influences long-term health and biochemical results to improve patient care. Participants with PA will undergo adrenal venous sampling through either the antecubital or femoral vein to identify whether aldosterone overproduction is unilateral or bilateral. This observational study evaluates the AVS procedure itself and its clinical outcomes, refining protocols and standardizing practices to optimize treatment decisions and patient prognosis. Throughout the study, researchers will monitor major cardiovascular events one year after AVS. They will also assess procedure success rates, complications, medication changes, blood pressure, heart and kidney function, and clinical outcomes over multiple years. The follow-up includes assessments at 1, 3, 6, 12, 18 months, and up to 10 years, enabling comprehensive evaluation of long-term effects and safety.

Age: 18Years +All Genders
76 locations
S

Actively Recruiting

Researchers are evaluating Shuxuening injection, a multi-target neuroprotective agent, to see its effects when added to intravenous thrombolysis therapy in patients with acute ischemic stroke. This large, multicenter, randomized, double-blind, placebo-controlled trial aims to assess the effectiveness and safety of Shuxuening injection in improving outcomes after stroke. Intravenous thrombolysis with rt-PA is the current standard treatment, but many patients still experience significant disability, so neuroprotective agents like Shuxuening may help reduce brain cell death. Participants will be randomly assigned to one of two groups one group will receive Shuxuening injection combined with intravenous thrombolysis, and the other will receive a placebo combined with intravenous thrombolysis. Both treatments involve a daily intravenous drip of 20 ml Shuxuening or placebo plus 250 ml of 0.9% sodium chloride for 10 to 14 days. The study plans to enroll 1380 patients within 6 hours of stroke onset from 50 centers across China. During the study, participants will be monitored closely with assessments including the modified Rankin Scale mRS score at 90 days to measure functional recovery, along with safety monitoring for adverse events over 90 days. Other evaluations include neurological function scores, quality of life surveys, and various safety outcomes. The trial will last for at least 90 days after treatment, with data collected on disability, recovery, and any side effects experienced.

Age: 18Years - 100YearsAll GendersPhase 3
82 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of group Guided Written Exposure Therapy for Complex Post-Traumatic Stress Disorder CPTSD in Chinese adolescents aged 10 to 18 years. This randomized controlled trial compares this therapy to supportive group therapy, aiming to understand how these treatments impact CPTSD symptoms. The study will recruit 120 participants, split evenly between the two treatment groups, to explore which approach better helps young people manage CPTSD. The group Guided Written Exposure Therapy for CPTSD GWE-C consists of 7 to 10 manualized group sessions delivered over 1 to 2 weeks. Sessions last between 60 and 90 minutes and include trauma processing, writing tasks, imagery dialogues, and self-compassion exercises. The comparison group receives seven supportive group sessions based on Rogerian psychotherapy, focusing on group activities, stress management, and emotional regulation without discussing individual trauma. Both interventions are conducted in groups of 6 to 10 participants, facilitated by counselors. Participants will complete assessments at baseline, immediately after treatment, and at one- and three-month follow-ups. The main outcomes are CPTSD symptom severity measured by the International Trauma Questionnaire through self-report and interviews. Additional evaluations include PTSD symptoms, depression, anxiety, and general difficulties. The trial monitors participant progress and symptom changes over approximately 15 weeks, providing detailed data on treatment effects and participant experiences.

Age: 10Years - 18YearsAll GendersPhase Not Applicable
4 locations